Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
BMS-986148
i
Other names:
BMS-986148, BMS986148, BMS 986148
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
BMS
Drug class:
Tubulin inhibitor, Mesothelin-targeted antibody-drug conjugate
Related drugs:
‹
albumin-bound paclitaxel (67)
A166 (6)
JNJ-8177 (3)
micellar paclitaxel (3)
REGN5093-M114 (3)
XMT-1660 (3)
vinblastine (3)
HZX-02-059 (2)
AR160 (2)
DJ 927 (2)
ACT-903 (1)
ADC2122 (1)
paclitaxel oral (1)
oral paclitaxel/encequidar (1)
YH012 (1)
hIMB1636-MMAE (1)
ABT-751 (0)
CBP-1018 (0)
paclitaxel polymeric micelle formulation (0)
paclitaxel liposomal (0)
liposomal paclitaxel (0)
paclitaxel nanoformulation (0)
paclitaxel-hyaluronic acid conjugate (0)
paclitaxel poliglumex (0)
bisphosphonate bound paclitaxel (0)
FID-007 (0)
CB 3304 (0)
BAY 59-8862 (0)
QR 207 (0)
ANG1005 (0)
BAY 94-9343 (3)
MORAb-109 (2)
RG7600 (2)
RC88 (0)
albumin-bound paclitaxel (67)
A166 (6)
JNJ-8177 (3)
micellar paclitaxel (3)
REGN5093-M114 (3)
XMT-1660 (3)
vinblastine (3)
HZX-02-059 (2)
AR160 (2)
DJ 927 (2)
ACT-903 (1)
ADC2122 (1)
paclitaxel oral (1)
oral paclitaxel/encequidar (1)
YH012 (1)
hIMB1636-MMAE (1)
ABT-751 (0)
CBP-1018 (0)
paclitaxel polymeric micelle formulation (0)
paclitaxel liposomal (0)
liposomal paclitaxel (0)
paclitaxel nanoformulation (0)
paclitaxel-hyaluronic acid conjugate (0)
paclitaxel poliglumex (0)
bisphosphonate bound paclitaxel (0)
FID-007 (0)
CB 3304 (0)
BAY 59-8862 (0)
QR 207 (0)
ANG1005 (0)
BAY 94-9343 (3)
MORAb-109 (2)
RG7600 (2)
RC88 (0)
›
Associations
News
Trials
Filter by
Latest
3years
A Study of BMS-986148 in Patients With Select Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=126, Terminated, Bristol-Myers Squibb | N=407 --> 126 | Active, not recruiting --> Terminated; Study terminated for business reasons not related to safety.
3 years ago
Clinical • Enrollment change • Trial termination
|
MSLN (Mesothelin)
|
MSLN positive
|
Opdivo (nivolumab) • BMS-986148
3years
Phase 1/2a trial of BMS-986148, an anti-mesothelin antibody-drug conjugate, alone or in combination with nivolumab in patients with advanced solid tumors. (PubMed, Clin Cancer Res)
BMS-986148 {plus minus} nivolumab demonstrated a clinically manageable safety profile and preliminary evidence of clinical activity, supporting additional studies combining directed cytotoxic therapies with checkpoint inhibitors as potential multimodal therapeutic strategies in patients with advanced solid tumors.
3 years ago
Clinical • P1/2 data • Journal • Combination therapy • PD(L)-1 Biomarker
|
MSLN (Mesothelin)
|
MSLN expression
|
Opdivo (nivolumab) • BMS-986148
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login